Stocktoria
Cabaletta Bio, Inc. CABA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-10-25
Cabaletta Bio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $142.7M | $97.2M | $55.4M | $39.3M | $32.5M |
| Operating income | -$172.2M | -$125.1M | -$74.7M | -$54.1M | -$46.3M |
| Interest expense | $2.0M | $748,000 | $0 | — | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$167.9M | -$115.9M | -$67.7M | -$53.0M | -$46.3M |
| EPS (diluted) | $-2.10 | $-2.34 | $-1.65 | $-1.81 | $-1.80 |
| Operating cash flow | -$131.1M | -$88.2M | -$53.5M | -$46.4M | -$34.1M |
| Free cash flow | -$132.3M | -$90.4M | -$54.2M | -$48.8M | -$35.3M |
| Cash & equivalents | $83.0M | $164.0M | $193.2M | $81.6M | $122.2M |
| Total assets | $165.1M | $185.0M | $253.7M | $117.0M | $126.3M |
| Total liabilities | $53.0M | $32.7M | $17.5M | $12.4M | $8.4M |
| Shareholders' equity | $112.1M | $152.3M | $236.2M | $104.5M | $118.0M |
Source: SEC EDGAR filings · CIK 0001759138 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.